EMEA Paper Reviews Patient and Consumer Involvement in Agency Activities
The European Medicines Agency recently released a reflection paper regarding the involvement of patients and consumers in the agency's activities.
The European Medicines Agency (EMEA) recently released a reflection paper regarding the involvement of patients and consumers in the agency’s activities. The agency issued a similar report in March 2008 to the EMEA Management Board and agreed to work with patient and consumer organizations in a more structured manner. The reflection paper proposes actions to further carry out this engagement.
The reflection paper notes that some of the current framework of interaction has been implemented (such as patient participation in scientific committees for orphan medicinal products and for pediatrics) but also notes areas that need more structure such as a procedure to systematically assess the need to involve patients in the Committee for Medicinal Products for Human Use (CHMP). The areas in which patient and consumer involvement have not increased generally are those areas that lack a legal basis for supporting patient interaction.
“The added value of patients and consumers in the scientific process of benefit/risk evaluation is [that] they enrich regulatory outcomes by complementing them with the views of those directly affected by regulatory decisions,” according to the paper’s executive summary. In addition, patients’ and consumers’ contributions build trust in the regulatory process because they foster higher levels of transparency.
The paper also discusses the compensation of patients and consumers who participate in agency activities. Currently, such work is done on a voluntary basis. Patients and consumers participating in an EMEA questionnaire confirmed their interest in remaining active in agency activities, including at the CHMP level, according to the paper.
Ultimately, the paper asks EMEA Management Board to revise “the framework of interaction between the agency and patients’ and consumers’ organizations” so that the legal basis for patient involvement is extended, and to “provide financial support to experts and delegates in need of it under certain conditions.”
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
